This is a randomized, rater blinded trial in people who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab.
The main purpose of this study by Biogen Idec is to find out the following when participants stop taking natalizumab for 24 weeks:
- How quickly the effects that natalizumab has on the immune system disappear
- When MS symptoms return
- If other drugs for MS may help control MS symptoms during the natalizumab-interruption period.
This study will also explore how quickly the effects of natalizumab return after resuming natalizumab dosing.
Major criteria for being accepted include:
- A diagnosis of a relapsing form of MS
- Treatment with natalizumab according to locally approved prescribing information
- Other protocol defined inclusion/exclusion criteria may apply.
For more information refer to identifier NCT01071083 at www.clinicaltrials.gov.
*
*
***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
(This will take 20-25 seconds and will empower you
with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews